Xeljanz XR(tofacitinib (extended-release))

Rheumatoid arthritis; psoriatic arthritis; ulcerative colitis. JAK inhibitor extended-release.

1 DTP program

From $3,204/mo cash · $0/mo copay card

1 platform

FDA-Approved Indications

Moderately-to-severely active rheumatoid arthritis in adultsActive psoriatic arthritis in adultsModerately-to-severely active ulcerative colitis in adults

Available direct-to-patient (DTP) programs

Sorted by price, lowest first. Always verify eligibility and pricing directly with the manufacturer.

Lowest price option

GoodRx cash + copay card (insured)

via PfizerForAll · Pfizer

$3,204/mo cash · $0/mo copay card

GoodRx cash: $3,203.70 (30 tabs, 63% off retail). Copay card: $0/mo for commercially insured (annual cap $4,000–$15,000).

Eligibility

Same as Xeljanz. GoodRx cash: US + PR. Copay card: commercial insurance required. 22mg dose carries elevated risk warnings.

Some benefits may not be available in: MA, CA

Visit Program

Last verified: Mar 2026

Not sure which Xeljanz XR program fits your situation?

Find My Options